Výsledky vyhledávání - "Deborah M. Boldt-Houle"

Akademický článek

Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer

Autor: Christopher J. D. Wallis, Kevin C. Chen, Stuart Atkinson, Deborah M. Boldt-Houle

Publikováno v: Advances in Urology, Vol 2024 (2024)

Background. The association between patient demographics and CV events after ADT using real-world data was evaluated. In addition to encompassing >30 times more patients than all previous MACE studies, this is the first study, to the best of our know

Externí odkaz: https://doaj.org/article/e08e34842a884eb59eec0908b94a3ce3

Zobrazit plný text záznamu

Plný text ve formátu HTML

ODP397 Small-volume, Subcutaneous, 6-month Leuprolide Acetate Effectively Reduces Growth Velocity to Prepubertal Levels in Children with Central Precocious Puberty

Autor: Karen O Klein, Stuart N Atkinson, Deborah M Boldt-Houle

Publikováno v: Journal of the Endocrine Society. 6:A607-A608

Introduction Clinical signs of puberty, growth rate, rate of bone maturation, luteinizing hormone concentrations and estimates of change in predicted adult height are the common variables for assessing efficacy of central precocious puberty (CPP) the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6979da372fd607ddf234412f8e5fb70e
https://doi.org/10.1210/jendso/bvac150.1261

Zobrazit plný text záznamu

MP37-18 LATE DOSING OF LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS AND TESTOSTERONE LEVELS >20NG/DL IN PROSTATE CANCER

Autor: Deborah M. Boldt-Houle, Stuart Atkinson, Jason Hafron, E. David Crawford

Publikováno v: Journal of Urology. 203

INTRODUCTION AND OBJECTIVE:Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used drugs for androgen deprivation therapy (ADT) for prostate cancer (PCa). Evidence sugges...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::39a6291ca655ea071f052e8c76d96691
https://doi.org/10.1097/ju.0000000000000886.018

Zobrazit plný text záznamu

Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer

Autor: Deborah M. Boldt-Houle, Stuart Atkinson, Judd W. Moul, Joseph Renzulli, Scott T. Tagawa

Publikováno v: BJUI compass. 1(2)

To assess the impact of patient age and weight on the pharmacokinetics (PK), testosterone (T) suppression and safety from four fixed dosing regimens (7.5, 22.5, 30, or 45 mg for 1-, 3-, 4-, or 6-months, respectively) of subcutaneous in situ gel deliv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ccb12e900db63f7492b35c633f77bb
https://pubmed.ncbi.nlm.nih.gov/35474709

Zobrazit plný text záznamu

6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children With Central Precocious Puberty

Autor: Erica A. Eugster, Bradley S. Miller, Stuart Atkinson, Deborah M. Boldt-Houle

Publikováno v: Journal of the Endocrine Society

Objective: Gonadotropin-releasing hormone (GnRH) agonists, such as intramuscular leuprolide acetate, triptorelin and the subcutaneous histrelin implant, are standard treatment for central precocious puberty (CPP). Implants require surgery and sometim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d4b980b2d713d2b432ff9273d2dd50c
http://europepmc.org/articles/PMC8090639

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání